Avelumab

Red

Brand Name(s):Bavencio

Indication:Untreated advanced Renal cell carcinoma

Rationale:1,2,3

Considered:Oct-20

Review Date:Oct-25

Comments:
NICE TA645 Avelumab with axitinib is recommended for the treatment of adult patients with advanced renal cell carcinoma if the conditions in the managed access agreement for avelumab with axitinib are followed. NICE states – more evidence on avelumab with axitinib is being collected until there is enough evidence to address the uncertainties about the treatment.